anti-Endoglin/CD28 bispecific antibodies (Twyce Therapeutics/BiconY Therapeutics/German Cancer Research Center/University Hospital Tuebingen)

N/A

Report date: 2026/03/19 16:53:20

Base Information

Drug Nameanti-Endoglin/CD28 bispecific antibodies (Twyce Therapeutics/BiconY Therapeutics/German Cancer Research Center/University Hospital Tuebingen)
Drug Alias Nameanti-Endoglin/CD28 costimulator (Twyce Therapeutics/BiconY Therapeutics/German Cancer Research Center/University Hospital Tuebingen)BiCo- 1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionT-cell-specific surface glycoprotein CD28 agonistsImmunostimulantsEndoglin modulators +[4] 
TargetsT-cell-specific surface glycoprotein CD28Endoglin
Therapy Area/IndicationsHormone-Resistant Prostate NeoplasmsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Hospital Tubingen
China Registration ClassN/A

Develop Information

Active CompaniesGerman Cancer Research Center (Dkfz)Twyce GmbHBiconY Therapeutics Gmbh +[4] 
Inactive CompaniesN/A
Active IndicationsHormone-Resistant Prostate NeoplasmsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A